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he Renal Patient With Coronary Artery Disease
urrent Concepts and Dilemmas
ajiv Gupta, MD, Yochai Birnbaum, MD, FACC, Barry F. Uretsky, MD, FACC
alveston, Texas
The patient with chronic kidney disease and coronary artery disease (CAD) presents special
challenges. This report reviews the scope of the challenge, the hostile internal milieu
predisposing to CAD and cardiac events, management issues, unresolved dilemmas, and the
need for randomized trials to allow for evidence-based treatment. (J Am Coll Cardiol 2004;
44:1343–53) © 2004 by the American College of Cardiology Foundationw
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phere is increasing recognition that chronic kidney disease
CKD)—of any degree—portends a worsened prognosis for
oronary artery disease (CAD) patients and that long-term
utlook in CKD patients is closely related to cardiovascular
vents. The value of most therapeutic interventions is less
ertain for CKD versus non-CKD patients because the
ormer have typically been excluded from randomized trials.
his review discusses the epidemiology, pathogenesis, clin-
cal manifestations, diagnostic work-up, treatment, progno-
is, and multiple conundrums regarding CAD patients with
KD.
AGNITUDE OF THE PROBLEM
growing threat. Chronic kidney disease has reached
pidemic proportions. More than 320,000 patients had
ialysis-requiring CKD in 1998; by 2010, this number may
xceed 650,000 patients (1). Patients with mild to severe
ecrease in glomerular filtration rate (GFR) constitute a
arger group, estimated in 1998 to be 13.3 million. Finally,
here are many CKD patients without decreased GFR (5.9
illion in 1998) (1).
The prevalence of CAD in CKD patients is high and is
major cause of morbidity and mortality (Table 1). In
emodialysis (HD) or peritoneal dialysis patients, preva-
ence is estimated at 40% with a 9% annual cardiovascular
ortality (2–4).
Renal transplant recipients (RTRs) have a lower CAD
revalence (15%) with an annual cardiovascular mortality of
.54%, twice the general population (2). This lower preva-
ence may be due to patients with fewer comorbidities and
ower CAD likelihood being chosen for transplantation.
The need for nomenclature uniformity has led to a recent
KD classification based on estimated GFR (Table 2). The
FR has been estimated by two formulae:
From the Cardiology Division, University of Texas Medical Branch, Galveston,
exas.
Manuscript received February 3, 2004; revised manuscript received June 21, 2004,0ccepted June 22, 2004.Cockcroft-Gault equation:
GFR
(140 age) lean body weight (kg)
72 stable sCr
 (0.85 for females)
here sCr  serum creatinine.
Modification of Diet in Renal Disease study equation:
GFR 170 [sCr]0.999 [age]0.176
 [0.762 if female] [1.180 if patient is black]
 [serum urea nitrogen]0.170 [albumin]0.318
KD: association with cardiovascular events and adverse
utcomes. Chronic kidney disease increases cardiovascular
vent risk and portends a worse outcome if an event occurs.
study of 3,106 acute myocardial infarction (AMI) patients
howed in-hospital mortality of 2% in normal renal func-
ion, 6% mild CKD, 14% moderate CKD, 21% severe
KD, and 30% in dialysis patients (p  0.001) with a
imilar trend long-term (5). A meta-analysis of ST-segment
levation AMI thrombolytic trials showed inverse correla-
ion between 30-day mortality and renal function (6).
atients with mild to moderate CKD and non–ST-segment
levation acute coronary syndrome (ACS) showed higher
0- and 180-day mortality than non-CKD patients (7,8).
ne-year mortality after AMI was 59% in dialysis patients
nd 24% in RTRs (9). In a post-AMI Medicare cohort
omprised of 130,099 patients, one-year mortality was 24%
ithout CKD, 46% with mild CKD, and 66% with mod-
rate CKD (p  0.001) (10).
Among CKD patients undergoing coronary angiography
ollowed long-term, the hazard ratio of AMI or death was
.3 for GFR 60 ml/min and 5.1 for GFR 30 ml/min
11). The CKD patients with “normal” angiography dem-
nstrated increased AMI (5.2% vs. 0.7% in non-CKD
atients, p  0.01) and mortality (24.7% vs. 3.9%, p 
.001) rates (11).
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Coronary Artery Disease in Renal Patients October 6, 2004:1343–53HE INTERNAL MILIEU IN CKD
he internal milieu in CKD favors CAD development and
aises the question whether renal insufficiency itself is a
AD risk factor.
iabetes mellitus. Diabetic nephropathy accounts for 40%
f new end-stage renal disease (ESRD). The 2001 U.S.
enal Data System reported a progressive rise in diabetic
SRD from 500/million in 1991 to 700/million in
999 (12). Diabetes mellitus (DM) is a strong risk factor for
therosclerosis progression, the mechanisms of vascular
njury being beyond the scope of this review.
ypertension. Hypertension prevalence in CKD ranges
rom 60% to 100%, depending on CKD cause and severity
nd population studied. Hypertension may cause or be an
ffect of CKD and confers an increased risk of cardiovas-
ular events in all patient subsets.
yperlipidemia. Hyperlipidemia prevalence is increased in
KD. Lipid abnormalities include increased serum triglyc-
rides, very low-density lipoprotein, and intermediate-
ensity lipoprotein and decreased high-density lipoprotein.
levated total cholesterol is found in 30% of CKD patients
ithout nephrotic syndrome and in 90% with nephrotic
yndrome compared with 20% of the general population.
ow-density lipoprotein cholesterol, calculated by the
riedewald formula, assumes a 5:1 triglyceride/cholesterol
atio in the very low-density lipoprotein particle and ignores
ntermediate-density lipoprotein. Hemodialysis patients
able 1. Estimated CAD Prevalence and Cardiovascular
ortality
Target Population
CAD
Prevalence (%)
Annual Cardiovascular
Mortality (%)
eneral population 5–12 0.28
ild to moderate CKD Unavailable 1
ialysis patients 40 9
enal transplant recipients 15 0.54
ource: References 2–5.
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitors
ACS  acute coronary syndrome
AMI  acute myocardial infarction
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
CCr  creatinine clearance
CIN  contrast-induced nephropathy
CKD  chronic kidney disease
CK-MB  creatine kinase-myocardial band
DM  diabetes mellitus
ESRD  end-stage renal disease
GFR  glomerular filtration rate
HD  hemodialysis
PCI  percutaneous coronary intervention
RR  risk ratio
RTR  renal transplant recipient
sCr  serum creatinineECAD  coronary artery disease; CKD  chronic kidney disease.ith normal calculated low-density lipoprotein cholesterol
ay actually have elevated intermediate-density lipoprotein
holesterol measured by ultracentrifugation. Because
ntermediate-density lipoprotein is atherogenic, the Friede-
ald formula probably underestimates the amount of
therogenic cholesterol and hence the risk of developing
therosclerosis. Increases in small and dense low-density
ipoprotein and oxidized low-density lipoprotein cholesterol
ave been reported in dialysis patients, which may increase
ardiovascular risk (13). Low serum cholesterol and albumin
evels in HD patients probably reflect poor nutritional status
nd are independent predictors of increased mortality.
alcium-phosphate product. Hemodialysis patients with
yperphosphatemia for 1 year and an elevated calcium-
hosphorous product have a higher mortality (14). Ganesh
t al. (15) found that hyperphosphatemic patients had 41%
ncreased risk of cardiovascular death and 20% increased risk
f sudden death. Hyperphosphatemia and high calcium-
hosphate product have been implicated in the pathogenesis
f cardiovascular calcification, which may correlate with
therosclerotic plaque burden and increased AMI incidence.
yperhomocysteinemia. Hyperhomocysteinemia is asso-
iated with an increased incidence of cardiovascular events
n ESRD and RTRs (16,17). Hyperhomocysteinemia may
roduce endothelial dysfunction; smooth muscle prolifera-
ion; platelet aggregation; activation of factors V, X, and
II; and modulation of tissue plasminogen activator, all
reating a prothrombotic environment. Plasma homocys-
eine increases, often to very high levels (100 mol/l;
ormal 12 mol/l) with GFR 70 ml/min (16). Homo-
ysteine is metabolized by either transsulfuration with pyr-
doxine as cofactor or by remethylation with transcobalamin
nd methyltetrahydrofolate, the active form of folate, as
ofactors. Deficiency of these water-soluble vitamins may
evelop from losses during dialysis and, coupled with poor
ral intake and decreased homocysteine renal clearance,
romoted hyperhomocysteinemia.
nflammation and oxidative stress. The role of systemic
nflammation and oxidative stress to the atherosclerosis
evelopment and cardiac events is currently being investi-
ated, and a discussion is beyond the scope of this review.
able 2. Classification of Chronic Kidney Disease
Stage Clinical Features
GFR
(ml/min/1.73 m2)*
1 Evidence of kidney disease in urine,
blood, or imaging with normal or
increased GFR
90
2 Mildly decreased GFR 60–89
3 Moderately decreased GFR 30–59
4 Severely decreased GFR 15–29
5 Renal failure 15 or renal
replacement
therapy
Modification of Diet in Renal Disease equation. Source: Reference 9.
GFR  glomerular filtration rate.nd-stage renal disease patients show activation of systemic
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October 6, 2004:1343–53 Coronary Artery Disease in Renal Patientsnflammation and increased oxidative stress (18). In non-
ialysis dependent CKD patients, blood levels of markers of
ystemic inflammation and oxidative stress increase as renal
ysfunction progresses (19).
mmunosuppressants. Corticosteroids for immunosup-
ression in RTR may induce insulin resistance and hyper-
ipoproteinemia. Cyclosporine increases low-density li-
oprotein cholesterol level in RTRs (20).
s CKD itself a risk factor for CAD? The question of
hether specific factors in CKD accelerate atherosclerosis is
nanswered, but clues suggest that this may be so. In the
omen’s Ischemia Syndrome Evaluation (WISE) study,
omen with chest pain (i.e., higher expected CAD preva-
ence) and mild CKD had a higher angiographic CAD
revalence compared with normal renal function patients
61% vs. 37%, p  0.001) (21). Chronic kidney disease may
ccelerate atherosclerosis further in the presence of type 2
M. In one study, diabetic RTRs had a lower ACS
ncidence after transplantation compared with pre-
ransplantation (22). Vascular disease in young ESRD
atients was related to inflammatory markers, hyperpara-
hyroidism, hyperphosphatemia, and hyperhomocysteine-
ia but not traditional risk factors (23). Asymptomatic mild
KD patients in the Cardiovascular Health Study showed
levated proinflammatory and prothrombotic parameters
19). These data emphasize the adverse internal environ-
ent and potential contribution of novel risk factors in the
evelopment and progression of CAD in CKD patients.
orphology of atherosclerotic plaque in CKD. Post-
ortem data of CKD vessels showed increased medial
hickness and smaller lumen area compared with age- and
ender-matched control subjects (24). Control plaques were
ostly fibroatheromatous, whereas CKD plaques were cal-
ified. An electron beam computed tomography study in
SRD adults showed coronary calcification in 92%; on
verage, calcium scores exceeded10-fold the 95th percen-
ile, the severity related to ESRD duration (23).
PECIAL ISSUES IN CKD PATIENTS
iagnosing ischemia and CAD. SYMPTOMS. Chest pain
pecificity for CAD is reduced in CKD as a result of
schemia from anemia, poorly controlled hypertension,
nd/or left ventricular hypertrophy as well as CAD. Con-
ersely, CKD patients with CAD may not experience chest
ain owing to diabetic or uremic neuropathy. Dyspnea on
xertion is also less specific for angina as it may be secondary
o anemia, volume overload, diastolic dysfunction, respira-
ory compensation for metabolic acidosis, and/or physical
econditioning.
ONINVASIVE EVALUATION. The electrocardiogram in
KD may display widened QRS and ST-T changes of left
entricular hypertrophy, volume overload, and electrolyte
bnormalities. Peak exercise capacity may be limited by
hysical deconditioning, musculoskeletal problems, poorly
ontrolled blood pressure, and anemia. Baseline electrocar- Niographic abnormalities and an inability to reach target
eart rate in exercise electrocardiographic testing lowers
ensitivity and specificity versus non-CKD patients (25).
obutamine stress-echocardiography in dialysis patients has
sensitivity of 75% to 95% and specificity of 76% to 86%
26). Dipyridamole radionuclide stress testing has a sensi-
ivity of 80% and specificity of 37% to 73% (25).
NVASIVE EVALUATION AND CONTRAST-INDUCED NEPHROP-
THY (CIN). The invasive evaluation of CAD in CKD
atients is complicated by an increased CIN risk, defined as
n absolute sCr increase 0.5 mg/dl or relative increase
25% above baseline after contrast administration (27–30).
he most important CIN risk factors are age 70 years,
re-existing CKD, and DM. In DM patients with CKD,
he CIN rate may exceed 25%.
Most studies comparing ionic high-osmolar with non-
onic low-osmolar contrast in patients without high-risk
eatures have shown no difference in renal outcome (27,31–
3). One study in mild CKD patients showed that the mean
nd maximal sCr increase was significantly lower with
opamidol (nonionic low-osmolar contrast) compared with
iatrizoate (ionic high-osmolar contrast) (28). Absolute sCr
hange (0.11 vs. 0.22 mg/dl) was small; the number of
atients developing renal failure was not significantly dif-
erent. In 1,196 patients, 3% (confined to CKD patients
lone or with DM) receiving iohexol (nonionic low-
smolar) developed nephrotoxicity compared with 7% (p 
.002) with diatrizoate (34). Dialysis was uncommon and
ot different between groups. A randomized study in 129
iabetics with mild to moderate CKD showed that iodixa-
ol (iso-osmolar non-ionic) decreased peak sCr after three
ays (0.13 mg/dl vs. 0.55 mg/dl, p  0.001) and seven days
0.07 mg/dl vs. 0.24 mg/dl, p  0.003) and significantly
owered CIN incidence (3% vs. 26%, p  0.002) versus
ohexol (29).
Thus, data suggest that non-ionic low-osmolar or iso-
smolar contrast decreases nephrotoxicity in diabetics and
KD patients, but the effect is relatively small. Universal
ow osmolar contrast use may add more than $195 million
o the nation’s health care costs (31), and the addition of
so-osmolar agents will further escalate costs.
Several agents have been shown to be ineffective in CIN
revention, including dopamine, mannitol, furosemide,
trial natriuretic peptide, calcium channel blockers, ami-
ophylline, and fenoldopam (30,35). One controlled ran-
omized trial comparing normal saline hydration alone with
aline and mannitol or furosemide showed that saline alone
as most successful in preventing CIN (30). Isotonic saline
ppears superior to hypotonic saline (36).
Some trials in CKD patients (Table 3) have shown
-acetylcysteine (an antioxidant) decreasing CIN inci-
ence, whereas others have not (37–46). In a meta-analysis
f 805 patients, N-acetylcysteine reduced CIN risk by 56%
p  0.02) (47). Based on low cost, simple regimen, low
dverse effect incidence, and clinical trial results,
-acetylcysteine may be used for CIN prevention. There
Table 3. Effect of N-Acetylcysteine for CIN Prevention
Citation (Ref.) Entry Criteria Procedure (Contrast) Dose of NAC
Hydration
Regimen*
CIN Criteria
Incidence of CIN
Increase sCr
> 0.5 mg%
Increase sCr
> 25% NAC % Placebo %
MacNeill et al. (37)
(n  57)
sCr  1.5 mg/dl Elective cors (iopromide/
ioxilan)
2 doses of 600 mg BID before and
3 doses after contrast
1 x 5 32
(p  0.046)
Kay et al. (38)
(n  200)
sCr  1.2 mg/dl
CCr  60 ml/min
Elective cors  PCI
(iopamidol)
600 mg BID  3 doses the day
before and 1 dose after contrast
2 x 4 12
(p  0.03)
Baker et al. (39)
(n  80)
sCr  1.36 mg/dl
CCr  50 ml/min
Elective cors  PCI
(iodixanol)
150 mg/kg over 30 min before and
50 mg/kg over 4 h after contrast
2 x 5 21
(p  0.045)
Diaz-Sandoval et al. (40)
(n  54)
sCr  1.4 mg/dl
CCr  50 ml/min
Elective cors (ioxilan) 600 mg BID  1 dose before and
then 3 doses after contrast
1 x x 8 45
(p  0.005)
Shyu et al. (41)
(n  121)
sCr  2 mg/dl
CCr  40 ml/min
Cors  PCI (iopamidol) 400 mg BID on day before and on
day of contrast
1 x 3.3 24.6
(p  0.01)
Tepel et al. (42)
(n  83)
sCr  1.2 mg/dl
CCr  50 ml/min
Computed tomography
(iopromide)
600 mg BID on day before and on
day of contrast
1 x 2 21
(p  0.01)
Oldemeyer et al. (43)
(n  57)
sCr  1.2 mg/dl
CCr  50 ml/min
Elective cors  PCI
(iopamidol)
1,500 mg BID started day before
and then every 12 h  4 doses
1 x x 8.2 6.4
(p  NS)
Durham et al. (44)
(n  79)
sCr  1.7 mg/dl ACS/elective cors
(iohexol)
1,200 mg 1 h before and 1,200 mg
3 h after contrast
1 x 26.3 22
(p  NS)
Briguori et al. (45)
(n  183)
sCr  1.2 mg/dl
CCr  70 ml/min
Elective cors/peripheral 
PCI (iopromide)
600 mg BID on day before and on
day of contrast
1 x 6.5 11
(p  0.22)
Allaqaband et al. (46)
(n  123)
sCr  1.6 mg/dl
CCr  60 ml/min
Cors/peripheral  PCI
(ioversol/iodixanol)
600 mg BID on day before and on
day of contrast
1 x 17.7 15.3
(p  NS)
*Hydration regimen: 1  0.45% saline 12 h before and 12 h after angiography; 2  0.90% saline 6–12 h before and 6–12 h after angiography.
ACS  acute coronary syndrome; BID  twice a day; CCr  creatinine clearance; CIN  contrast-induced nephropathy; cors  coronary angiography; NAC  N-acetylcysteine; PCI  percutaneous coronary intervention; sCr 
serum creatinine.
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trate efficacy.
Contrast-induced nephropathy is usually non-oliguric.
reatment includes fastidious maintenance of fluid balance,
voidance of nephrotoxic agents, and monitoring of renal
unction and electrolyte status. Dialysis is necessary in only
small percentage (0.4% to 0.8% of patients undergoing
ercutaneous coronary intervention [PCI]) (48). Most pa-
ients recover by one to three weeks, but a small percent do
ot, or only partially. Patients with mild to moderate CKD
ho develop CIN after PCI show increased one-year
ortality (45% if dialysis is required, 35% if dialysis is not
equired, and 19% if sCr does not rise, p  0.001) (49).
alue of biomarkers in CKD. RELIABILITY OF BIOMARK-
RS FOR DIAGNOSING AMI. Creatine kinase-myocardial
and (CK-MB) elevations have been found on routine
esting in dialysis patients without clinical or electrocardio-
raphic evidence of AMI. It is unclear whether these
levations represent false positives, ongoing myocardial
amage, or reduced CK-MB clearance.
Troponin measurement may have similar limitations. In
ne study, cardiac troponin was found to be the most
onsistent AMI marker in all CKD strata including dialysis
atients and was more sensitive and had a higher negative
redictive value than myoglobin and CK-MB (50). How-
ver, sporadic or persistent elevations have also been seen in
roponin T and I in asymptomatic HD patients.
REDICTING PROGNOSIS WITH BIOMARKERS. Studies have
valuated the relationship of biomarkers to prognosis in
CS, post-PCI, and asymptomatic CKD patients. In 7,033
CS patients in the Global Utilization of Streptokinase and
issue Plasminogen Activator for Occluded Arteries
GUSTO) IV trial, troponin T predicted increased AMI or
eath risk at one month regardless of creatinine clearance
CCr) (51).
The CK-MB elevation after PCI in CKD patients is
ssociated with increased mortality and in-hospital compli-
ations (52).
An increase in predialysis serum troponin T and/or I was
ssociated with a twofold to fivefold increase in two-year
ortality in asymptomatic HD patients (53). In HD pa-
ients without ACS, troponin T correlated with left ven-
ricular mass and all-cause and cardiovascular mortality (54).
urther, in such patients, increasing troponin T and
-reactive protein levels were independently associated with
n increased risk of death, and their combination predicted
he highest death risk (55). The exact role of troponin
esting for risk stratification of asymptomatic HD patients is
ttractive but undefined. Also unclear is the appropriate
valuation and management of CKD patients with asymp-
omatic serum CK-MB and/or troponin elevation.
AD screening in renal transplant candidates. Cardio-
ascular events cause 35% to 50% of all deaths after renal
ransplantation (56). The purpose of CAD screening is
wo-fold: 1) to determine surgical risk, and 2) to estimate
urvival after transplantation. It should be noted that there fire no large-scale trials demonstrating that “prophylactic”
evascularization improves long-term outcome after trans-
lantation. Because there is a limited organ supply and
atients without CAD are likely to have better long-term
utcome, should screening exclude CAD patients from
ransplantation? Alternatively, should aggressive screening
nd coronary revascularization be performed to optimize
ong-term outcome after transplantation for patients who
urvive the revascularization procedure? What is clear is that
atients who manifest ischemia on pre-transplant stress
esting have a higher cardiac event and mortality risk in
ong-term post-transplantation follow-up (57). These data
mphasize the quandary on how to evaluate and treat these
atients.
The American Society of Transplant Physicians has
ormulated CAD screening guidelines (58). Transplant
andidates with angina and diabetics with evidence of
schemia should usually undergo pre-transplant coronary
ngiography without prior noninvasive testing (58). Routine
re-transplant coronary angiography in asymptomatic dia-
etics is uncertain. For asymptomatic patients with CAD by
istory or multiple risk factors, noninvasive testing may help
n assessing the post-transplant cardiac risk. If the stress test
s abnormal, coronary angiography is recommended (58).
merican Society of Transplant Physicians guidelines sug-
est revascularization before transplantation in patients with
critical” lesions based on a small randomized trial in 26
symptomatic diabetics (58,59).
ptimizing medical management. There is underutiliza-
ion of aspirin, beta-blockers, angiotensin-converting en-
yme inhibitors (ACEI), glycoprotein IIb/IIIa receptor
ntagonists, diagnostic coronary angiography, thrombolytic
herapy, and PCI in CKD patients with AMI or ACS
60,61). This may relate to physician concern regarding
leeding risk, worsening of renal function, lack of evidence
or use of certain drugs, associated comorbidities, and
enerally worsened outcomes in CKD patients. Dose ad-
ustment in cardiac medications may be necessary (Table 4).
NTICOAGULATION. Management of ACS in CKD pa-
ients is the same as in the general population with few
xceptions. Aspirin is recommended, although no prospec-
ive efficacy or safety data have dealt specifically with CKD
atients. Unfractionated heparin is preferred over low-
olecular-weight-heparin, which may accumulate in renal
ailure and for which adequate data are unavailable. Direct
hrombin inhibitors are cleared partially by the kidney,
rging caution until more data are available. A meta-
nalysis suggests that at least for bivalirudin, the drug is
qually, or more, effective than unfractionated heparin and
roduces less bleeding (62). Safety data on glycoprotein
Ib/IIIa inhibitors are limited as a result of the exclusion of
KD patients from most clinical trials. Among mild to
oderate CKD patients in the Platelet-Receptor Inhibition
or Ischemic Syndrome Management in Patients Limited by
nstable Signs and Symptoms (PRISM-PLUS) trial, tiro-
ban plus heparin was well tolerated and effective in
Table 4. Dose Modification of Selected Cardiovascular Drugs Commonly Used in CAD in CKD
Drug Class Specific Drug
Adjustment for CKD
(% Dose Compared With Normal GFR Dose*)
Supplement for HD† Comments10–50 ml/min 10 ml/min
Beta-blocker Atenolol 50 25 25–50 mg Carvedilol, metoprolol, labetalol, propranolol,
esmolol: no changeSotalol 30 15–30 80 mg/dose after HD
Nadolol 50 30 40 mg
ACEI — 50–75 25–50 20–30%/dose after HD
ARB — 100 75 None for fosenopril or benazepril —
Ca-blockers — 100 100 None —
Adrenergic modulators Methyldopa q8–12 h q12–24 h 250 mg Clonidine, doxazosin, prazosin: no change
Vasodilators Hydralazine q8 h q8–16 h None Minoxidil, nitroprusside: no change
Diuretics Thiazides 100 Avoid NA Furosemide, bumetanide, torasemide,
metolazone: no changeSpironolactone q12–24 h Avoid NA
Triamterene 100 Avoid NA
Ethacrynic acid q8–12 h Avoid NA
Lipid-lowering agents Rosuvastatin 100 25 U Atorvastatin, simvastatin, lovastatin, fluvastatin,
pravastatin, gemfibrozil, colestipol,
cholestyramine, ezetimibe: no change
Fenofibrate 25–50 Avoid Avoid
Nicotinic acid 50 25 U
Anticoagulants/lytic LMWH 100 50 or avoid U Unfractionated heparin, warfarin, streptokinase,
t-PA: no change
Bivalirudin 80 10–30 U
Antiplatelet agents Eptifibatide 100 bolus; 50 infusion Avoid None Aspirin, abciximab, clopidogrel, ticlopidine: no
changeTirofiban 50–100 50
Anti-arrhythmics Disopyramide q12–24 h q24–48 h None Adenosine, amiodarone, lidocaine, ibutilide,
moricizine, propafenone: no changeFlecainide 100 50–75 None
Bretylium 25–50 25 None
Procainamide q6–12 h q8–24 h 200 mg
Mexiletine 100 50–75 None
Quinidine 100 75 None
Inotropes Dopamine 100 50–75 U Dobutamine: no change
Epinephrine 100 50–75 U
Milrinone 100 50–75 U
Norepinephrine 100 50–75 U
Phenylephrine 100 50–75 U
Miscellaneous Digoxin 25–75 q36 h 10–25 q48 h/avoid None Serum digoxin level 12 h after last dose for
guidanceISMN, ISDN 100 100 Dose after HD
*CKD patients with estimated GFR 51 ml/min can be given listed medications in same dosages as normal GFR patients. †Continuous ambulatory peritoneal dialysis requires no supplementation.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; CAD  coronary artery disease; CKD  chronic kidney disease; GFR  glomerular filtration rate; HD  hemodialysis; ISDN  isosorbide
dinitrate; ISMN  isosorbide mononitrate; LMWH  low-molecular-weight heparin; NA  not applicable; q  every; t-PA  tissue plasminogen activator; U  unknown.
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ients in the Enhanced Suppression of the Platelet IIb/IIIa
eceptor with Integrilin Therapy (ESPRIT) trial, bleeding
isk and treatment effect with eptifibatide were similar to
hat in patients with normal renal function (63). A retro-
pective study in mild CKD PCI patients showed no
ignificant differences in bleeding or the combined end
oint of death and AMI between abciximab and control
64). Thienopyridine studies have excluded CKD patients,
o efficacy and safety in this group are inferred.
ANAGEMENT OF HYPERTENSION. The seventh report of
he Joint National Committee on prevention, detection,
valuation, and treatment of high blood pressure recom-
ends that CKD patients should have a blood pressure
130/80 mm Hg (65). The National Kidney Foundation
ecommends 125/75 mm Hg for CKD patients with
roteinuria 1 g/day (66). However, the relationship be-
ween blood pressure and mortality in HD patients may
xhibit a “U”-shaped distribution wherein not only high
180 mm Hg) but also low (110 mm Hg) systolic blood
ressure is associated with increased mortality (67).
Hypertension in CKD patients, especially those on dial-
sis, is volume-dependent. Hence maintenance of fluid
alance is paramount. Examination of neck veins, edema,
nd body weight can aid in managing fluid status.
CEI. Angiotensin-converting enzyme inhibitors decreased
0-day mortality (relative risk 0.64) in dialysis patients with
MI, an effect similar to non-dialysis patients (61).
ngiotensin-converting enzyme inhibitors decrease the
rogression of nephropathy in type 1 and 2 diabetes (68,69)
nd non-diabetic renal disease (70). In the Heart Outcomes
revention Evaluation (HOPE) trial, risk reduction for
ardiovascular death, all-cause mortality, and heart failure
ospitalizations with ramipril was greater for CKD than
on-CKD patients (71). These agents should be used
autiously because they may induce hyperkalemia in non-
ialysis patients with mild to severe CKD.
NGIOTENSIN RECEPTOR BLOCKERS. Renoprotection from
ngiotensin receptor blockers has been demonstrated in
KD patients but cardioprotection has not. Renoprotection
ppears to be independent of blood pressure reduction (72).
n a randomized trial of 1,513 CKD patients with type 2
M, nephropathy progression was reduced by losartan but
ardiovascular death incidence was similar to placebo (72).
n a trial of irbesartan, amlodipine, or placebo in 1,715
KD patients with hypertension and type 2 DM, irbesartan
fforded renoprotection but not cardioprotection (73).
ased on lack of proven cardioprotective effect of angioten-
in receptor blockers in CKD patients, ACEI are preferred
hen possible.
ETA-BLOCKERS. Beta-blockers appear to retain their cardio-
rotective effects in CKD patients. In an analysis of a Medicare
atabase of over 200,000 mild CKD patients, there was a 35%
eduction in mortality with beta-blockers (74).
REATMENT OF HYPERLIPIDEMIA. Target serum low-densityipoprotein cholesterol in CAD patients is100 mg/dl. Statin rose reduction is required in RTRs taking cyclosporine or
acrolimus. It is not clear whether isolated hypertriglyceridemia
r low levels of high-density lipoprotein cholesterol should be
reated with drugs in CKD patients.
REATMENT OF HYPERHOMOCYSTEINEMIA. Recom-
ended daily allowances of folate (5 mg/day), transcobal-
min (0.4 mg/day), and pyridoxine (50 mg/day) normalize
omocysteine level in mild to moderate CKD patients and
TRs, but only mildly affect homocysteine levels in dialysis
atients. Although higher homocysteine levels are associ-
ted with increased cardiovascular events in CKD patients,
ata demonstrating reduction in ischemic events or death
ith treatment in CKD or the general population are
acking. Nevertheless, it seems reasonable to normalize
lasma homocysteine if possible.
ANAGEMENT OF ANEMIA. Anemia may increase angina
everity and left ventricular hypertrophy and decrease exer-
ise tolerance, and its correction improves these abnormal-
ties (75). The Normal Hematocrit Trial showed that
atients with ESRD and CAD or heart failure treated with
rythropoietin to a target hematocrit of 42% had a higher
isk ratio (RR) (1.3) for the end points of death or nonfatal
MI compared with a targeted hematocrit of 30% (76).
lternatively, a large Medicare study of HD patients using
rythropoietin demonstrated decreased risk of cardiac mor-
ality with a hematocrit of 30% to 33%, and an even lower
isk with 33% to 36% (77). The National Kidney Founda-
ion Dialysis Outcomes Quality Initiative recommends a
arget hematocrit of 33% to 36% (78).
REATMENT OF HYPERPHOSPHATEMIA. Control of
alcium-phosphate product and hyperparathyroidism seem
easonable goals although efficacy data are lacking. Low-
hosphate diet and use of phosphate binders may be helpful.
OLE OF ANTIOXIDANTS. Antioxidants for cardioprotec-
ion have demonstrated conflicting results. The Secondary
revention with Antioxidants of Cardiovascular disease in
nd stage renal disease (SPACE) trial demonstrated that
itamin E use in HD patients was associated with a 54%
ecrease in the combined end point of AMI, ischemic
troke, symptomatic peripheral vascular disease, and unsta-
le angina (79). Other studies have not demonstrated a
eneficial effect of vitamin E (80). N-acetylcysteine in HD
atients decreased the composite end point of fatal/non-
atal AMI, cardiovascular death, need for revascularization,
schemic stroke, and symptomatic peripheral vascular dis-
ase versus placebo (28% vs. 47%, p  0.03) (81). Although
fficacy trials with antioxidants have been disappointing in
on-CKD patients, the increased oxidant stress in CKD
ay provide the environment for antioxidants to be cardio-
rotective. Clearly more data are required before any anti-
xidant can be recommended.
evascularizing CKD patients. PCI. There is a striking
ack of comparison of CAD treatments in CKD patients.
mall studies using balloon angioplasty in HD patients have
hown initial angiographic success of 56% to 96% with high
estenosis rates (60% to 81%) (82). Procedural advances and
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90%) and lower restenosis rates (31% to 36%) (83).
rug-eluting stents may reduce restenosis rates further,
lthough data are currently unavailable.
Mortality risk during PCI hospitalization increases with
KD as well as DM and appears additive: DM()CKD()
.7%, DM()CKD() 1.0%, DM()CKD() 2.3%,
M()CKD() 3.7% (84). The CKD patients have
igher one-year mortality after PCI than non-CKD pa-
ients (85), a trend observed through four-year follow-up
86). In 5,327 post-PCI patients, one-year mortality was
.5% (RR 1.5) with CCr 70 to 90 ml/min, 3.6% (RR 2.3)
ith CCr 50 to 69 ml/min, 7.8% (RR 3.7) with CCr 30 to
9 ml/min, 18.3% with CCr 30 ml/min, and 19.9% (RR
.9) in dialysis patients (p  0.001) (87). Percutaneous
oronary intervention use in AMI (88) showed a higher
0-day death rate (7.5%) in CKD versus non-CKD patients
0.8%, p 0.0001). In multivariable analysis, CKD had the
ighest RR (5.7) for mortality of all factors studied. The
KD patients undergoing saphenous vein graft interven-
able 5. CABG Outcomes in HD Patients
Investigators (Ref.) n
Perioperative
Mortality
(%)
Long-Term Mortality (%)
1 yr 2 yr 3 yr 5 yr
arshall et al. (91) 25 8 17 — 31 52
psahl et al. (92) 39 2.6 8 8 — —
atiuk et al. (93) 25 20 5 23 30 30
wen et al. (94) 21 9 16 55 — —
inehart et al. (95) 60 3 24 34 48 60
akayama et al. (96) 51 7.8 11 — 16 29
ranga et al. (97) 44 11.4 16 22 36 68
ishida et al. (98) 105 4.8 — — — 40
ujii et al. (99) 23 8.6 32 — 58 65
otal/mean 738 9.6 16 28 36 48
ABG  coronary artery bypass graft surgery; HD  hemodialysis.
able 6. Comparison of CABG and PCI in HD Patients
Study (Ref.)
n
In
M
CABG PCI CABG
inehart et al. (95) 60 24 —
oyanagi et al. (109) 23 20 0
imsir et al. (110) 22 19 4.5
erzog et al. (111) 7,419 6,887 12.5
girbasli et al. (112) 130 122 6.9
vens et al. (113) 65 40 4.8
erzog et al. (114) 6,668 4,836 8.6
 (4,280)
x et al. (115)* 290 —
 (all)
Arterial Revascularization Therapies Study substudy; †end point was combined inci
  stents; PCI  percutaneous coronary intervention. Other abbreviations as in Tablions also show a higher in-hospital and one-year mortality
89). Chronic kidney disease patients with ST-segment
levation AMI showed a lower 30-day mortality with
hrombolysis (8.3%) than PCI (37.1%, p  0.04) (90),
mphasizing the uncertainty of the preferred AMI treat-
ent in CKD patients.
ORONARY ARTERY BYPASS GRAFT SURGERY (CABG). Coro-
ary artery bypass graft surgery perioperative mortality in
ialysis patients is approximately 7% to 10%, at least three to
our times non-CKD patients, and five-year mortality is
stimated at 48% versus 15% in non-CKD patients (Table
) (91–99). Most studies are retrospective, have small
ample size, and are unadjusted. In studies with adjustment,
KD remains a highly significant predictor for decreased
ong-term survival (100). Not unexpectedly, HD-dependent
iabetics suffer worse long-term outcomes after CABG than
on-diabetics (101).
Coronary artery bypass graft surgery outcomes in mild or
oderate CKD patients are limited. Chronic kidney disease
atients (vs. non-CKD patients) had longer in-hospital and
ntensive care unit stay and more frequent postoperative
ialysis (102). In a prospective 1,427-patient study, sCr
1.5 mg/dl increased the length of hospital stay and the
eed for postoperative dialysis (103). In-hospital mortality
ncreased with a rise in preoperative sCr (2.3%, sCr 1.5
g/dl; 18.5%, sCr 1.7 mg/dl). In a prospective study of
,222 mild CKD patients, 7.7% had postoperative renal
ysfunction associated with prolonged intensive care unit
nd hospital stays and increased mortality (104).
Long-term outcomes in the Bypass Angioplasty Revascu-
arization Investigation (BARI) showed a higher risk of all-
ause (RR 2.2) and cardiac (RR 2.8) deaths and increased
ardiac admissions in CKD patients who underwent CABG or
CI, with 70% with CKD and DM dead by 7 years (105). In
spital
ty (%)
Freedom From
Angina (%)
Event-Free
Survival (%)
PCI CABG PCI CABG PCI
— 77 60 66 51
(6 mo) (2 yrs)
0 — — 70 18
(5 yrs)
5.3 87 40 67 69
(1.5 yr) (1.5 yr)
5.4 — — 71 62
(2 yrs)
1.6 — — 27 23
(1 yr)
0 90 29 86 82
(2 yrs) (2 yrs)
6.4 — — 56 48
1%)  (48)
(2 yrs)
— — — 72.7† 71.5
(3 yrs)
of death, myocardial infarction, or stroke.-Ho
ortali
 (4.
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October 6, 2004:1343–53 Coronary Artery Disease in Renal Patientsnother analysis of mild to moderate CKD patients, in-
ospital CABG mortality was 11% and actuarial survival at 10
ears was 32%, similar to dialysis patients (106).
There have been very few studies addressing CABG out-
omes in RTRs. In a study of 131 RTRs, there was a
erioperative mortality of 3.2% (107) with no deaths during
ve-year follow up. In 45 RTRs undergoing PCI or CABG,
ctuarial survival at 1, 3, and 5 years was 93%, 78%, and 60%
108).
OMPARISON OF CABG AND PCI. Studies comparing
ABG with PCI in HD patients are all non-randomized
nd retrospective. There may be an increased perioperative
ortality but better long-term survival and freedom from
ngina with CABG compared with balloon angioplasty
Table 6) (109–115). A preliminary report from a large
rospective trial comparing stenting and CABG in patients
ith multi-vessel disease suggests similar outcomes. A
on-randomized study in CKD patients with estimated
FR 60 ml/min with ACS showed that PCI was asso-
iated with improved survival compared with CABG or
edical therapy (116).
ONCLUSIONS
his review has highlighted that CAD is widely prevalent in
KD and that CAD patients with CKD have a worsened
rognosis. The current challenge is to study the CAD
atient with CKD in prospective randomized trials to
rovide an evidence-based approach to therapy. In the
bsence of such information, aggressive control of CAD risk
actors and timely intervention for symptomatic CAD is
uggested. In view of the profound effects that renal dys-
unction has on the natural history of CAD, it remains to be
een whether CKD itself will come to be regarded as a
istinct risk factor for CAD.
eprint requests and correspondence: Dr. Barry F. Uretsky,
niversity of Texas Medical Branch at Galveston, Department of
nternal Medicine, 5.106 John Sealy Annex, 301 University
oulevard, Galveston, Texas 77555-0553. E-mail: buretsky@
tmb.edu.
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